Literature DB >> 1328822

The inhibition of low-density lipoprotein oxidation by 17-beta estradiol.

V A Rifici1, A K Khachadurian.   

Abstract

The antioxidant activities of 17-beta-estradiol (E2) and other steroid hormones were studied by determining their effect on copper-catalyzed (cell-free) and mononuclear cell-mediated oxidation of low-density lipoproteins (LDL), as measured by the production of thiobarbituric acid-reactive substances (TBARS). The oxidation of LDL increased linearly with copper concentrations ranging from 0 to 10 mumol/L. E2 at a concentration of 1 mumol/L inhibited LDL oxidation by 37% to 62% at the various concentrations of copper. In a time-course study, E2 at 1 mumol/L delayed the onset of LDL oxidation in the presence of 5 mumol/L copper. E2 (1 mumol/L) inhibited TBARS production catalyzed by 5 mumol/L copper by 54%, compared with 60% inhibition by 1 mumol/L butylated hydroxytoluene (BHT), a known inhibitor of lipid peroxidation. Estriol at 5 mumol/L decreased LDL oxidation by 49%. Dehydroepiandrosterone (DHEA), testosterone, and estrone had no significant effects. E2 was also an effective inhibitor of mononuclear cell (MNC)-mediated oxidation of LDL, but had no effect on superoxide production by these cells. The onset of TBARS formation from cell-mediated LDL oxidation was also delayed by incubation with 1 mumol/L E2. The results indicate that estrogen may protect against atherosclerosis by inhibiting lipoprotein oxidation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328822     DOI: 10.1016/0026-0495(92)90295-l

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  22 in total

1.  Combined oestrogen-progestogen replacement therapy does not inhibit low-density lipoprotein oxidation in postmenopausal women.

Authors:  Y Wen; M C Doyle; L A Norris; M M Sinnott; T Cooke; R F Harrison; J Feely
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 2.  Postmenopausal hormone replacement therapy and cardiovascular risk reduction. A review.

Authors:  S D Kafonek
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 3.  Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease.

Authors:  N C Inestrosa; M P Marzolo; A B Bonnefont
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

4.  The orientation and dynamics of estradiol and estradiol oleate in lipid membranes and HDL disc models.

Authors:  Alexander Vogel; Holger A Scheidt; Scott E Feller; Jari Metso; Robert M Badeau; Matti J Tikkanen; Kristiina Wähälä; Matti Jauhiainen; Daniel Huster
Journal:  Biophys J       Date:  2014-07-01       Impact factor: 4.033

5.  Correlation between genetic polymorphisms within the MAPK1/HIF-1/HO-1 signaling pathway and risk or prognosis of perimenopausal coronary artery disease.

Authors:  Nan Guo; Nan Zhang; Liqiu Yan; Xufen Cao; Jiawang Wang; Yunfei Wang
Journal:  Clin Cardiol       Date:  2017-04-26       Impact factor: 2.882

6.  Antioxidant: a new role for RU-486 and related compounds.

Authors:  S Parthasarathy; A J Morales; A A Murphy
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

7.  Effect of estrogen replacement therapy on lens epithelial cell apoptosis in an experimental rat model.

Authors:  Fatih Ozcura; Sema Oruç Dündar; Emel Dikicioğlu Cetin; Nahit Beder; Mehmet Dündar
Journal:  Int Ophthalmol       Date:  2009-12-05       Impact factor: 2.031

8.  Effects of oral, vaginal, and transdermal hormonal contraception on serum levels of coenzyme q(10), vitamin e, and total antioxidant activity.

Authors:  Prabhudas R Palan; Felix Strube; Juraj Letko; Azra Sadikovic; Magdy S Mikhail
Journal:  Obstet Gynecol Int       Date:  2010-08-09

9.  Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model.

Authors:  G Mittal; G Chandraiah; P Ramarao; M N V Ravi Kumar
Journal:  Pharm Res       Date:  2008-09-12       Impact factor: 4.200

10.  17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice.

Authors:  Amparo C Villablanca; Amy Tenwolde; Michael Lee; Melissa Huck; Shannon Mumenthaler; John C Rutledge
Journal:  J Cardiovasc Transl Res       Date:  2009-05-02       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.